Q-omics provides the consensus-scored SIGLEC20P profile across patient tissues and cancer cell-line models. SIGLEC20P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SIGLEC20P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, SIGLEC20P RNA expression shows 6,745 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, HNSC, and STAD as cancer lineages where SIGLEC20P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLEC20P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLEC20P survival associations across molecular data types. SIGLEC20P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLEC20P RNA expression–survival associations across cancer types. High SIGLEC20P expression shows unfavorable associations in ACC, LUSC, BLCA and UVM, but favorable associations in PAAD and UCS. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify PAAD as the clearest survival context for SIGLEC20P RNA expression.
This table summarizes SIGLEC20P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SIGLEC20P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLEC20P shows lower tumor expression in LUAD, LUSC and THCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher SIGLEC20P RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .021).
This table shows molecular features associated with SIGLEC20P in patient tissues and cancer cell lines. In patient samples, SIGLEC20P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
